AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05368181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
Study NCT05635292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-CBT
Description: 8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
Study NCT04504643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-assisted circuit training
Description: Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks
Study NCT04504643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional circuit training
Description: Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks
Study NCT04504643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking
Description: Classic nordic walking 3 times a week for one hour during 8 weeks
Study NCT06540001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated visual acuity
Description: The automated visual acuity device is developed in collaboration with Tan Tock Seng Hospital, Singapore Institute of Technology and Nanyang Technological University. It uses artificial intelligence for pose estimation and speech recognition to infer if the participant is reading the correct letters displayed on the screen.
Study NCT05043402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navicixizumab
Description: navicixizumab IV
Study NCT05043402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xerna™ TME Panel
Description: RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
Study NCT05043402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xerna™ TME Panel
Description: RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
Study NCT06516627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Labels
Description: Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best).
Study NCT06516627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spectrum Labels
Description: All products will display an expanded Guiding Stars label that show an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best).
Study NCT06516627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA High In Labels
Description: Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.
Study NCT06516627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA Traffic Light Labels
Description: All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red.
Study NCT06667479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (CO)
Description: Participants will be encouraged to maintain their current diet and exercise across the duration of the 4 week intervention. Participants will still be subjected to the pre- and post-intervention data collection session.
Study NCT06666933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE (eating is allowed from 8am to 4pm without limitation in calories) with metformin 1g bid po for 6 weeks
Study NCT06666933 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Taking metformin 1g bid po only for 6 weeks as control
Study NCT06666933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Taking metformin 1g bid po only for 6 weeks as control
Study NCT06667973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients.
Study NCT06667947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: For the caudal block, a caudal needle was used by the same anesthesiologist after the patients were placed in the left lateral decubitus position.
Study NCT06667726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06667726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodopa F 18
Description: Given IV
Study NCT06667726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06666868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained CARD
Description: This group is using CARD for the 2nd year in a row in participating pharmacies as the vaccination delivery framework (It was used in the 2023-2024 fall/winter vaccination season and is now being sustained in the 2024-2025 fall/winter vaccination season).
Study NCT06666868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First-time CARD
Description: CARD is being used for the 1st time in participating pharmacies as the vaccination delivery framework (2024-2025 fall/winter vaccination season).
Study NCT06674655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery Plus Therapeutic Exercise
Description: This group will perform three days of lumbo-pelvic motor control exercise intervention along with a motor imagery intervention program during active breaks between exercises.
Study NCT04395183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan 100 MG
Description: 5-HTP 100mg PO BID
Study NCT04395183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: Creatine monohydrate 5g PO qday
Study NCT04395183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matched to 5-HTP
Description: placebo matched to 5-HTP
Study NCT04395183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
Study NCT06050902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subclavian venipuncture for catheter placement using the needle-steering device
Description: 1. Navigation software is implemented in an ultrasound machine.~2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~4. Real time needle guidance on the ultrasound screen during the puncture.
Study NCT06218251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections
Study NCT05841238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05356390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week.
Study NCT05356390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy techniques
Description: Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week.
Study NCT06214858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN211 tablets
Description: SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
Study NCT06214858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN211 placebo tablets
Description: placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
Study NCT05007561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: oral naltrexone
Study NCT05007561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral sugar pill
Study NCT04963894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home functional balance physiotherapy
Description: Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
Study NCT04963894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
Study NCT06139068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative Group Counseling
Description: Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling was applied to the intervention group once a week in 8 sessions. The intervention was completed face to face, in a calm, quiet and bright environment, with a round seating plan. One session lasted 90 minutes. Each session was completed in two parts with a 10-minute break.
Study NCT06139068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stress coping interviews
Description: In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
Study NCT05156502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser (Pixel CO2-Alma)
Description: The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
Study NCT05156502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Laser (Pixel CO.2-Alma)
Description: Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
Study NCT05995301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine in Transversus abdominis plane
Description: This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
Study NCT05995301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine in Local infiltration at port site
Description: This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
Study NCT04466215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miricorilant
Description: 900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
Study NCT04466215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Six placebo tablets taken orally once daily for two weeks
Study NCT05089435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EZYPRO® ECG Recorder
Description: EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
Study NCT06437093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEACHING RELACTATION TECHNIQUES
Description: In our midwifery intervention, the mother was firstly educated about breastfeeding and relactation, using educational brochures prepared by the researchers. Afterwards, the mother was taught nipple stimulation, skin-to-skin contact and finger feeding method, and the first feeding of the baby was performed together with the mother. After this first intervention in the FHC, all interventions were performed at home. The follow-ups continued for 15 days with one day of telephone support and one day of home visit. Since the majority of mothers did not accept video calls (privacy, etc.), telephone support was provided only verbally.
Study NCT06674655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: This group will perform a lumbo-pelvic motor control exercise program for three consecutive days.
Study NCT06674655 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Minimal intervention
Description: This group will carry out a therapeutic counseling and minimal education intervention during a one-day intervention.
Study NCT06621758 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Questionnaire regarding biomarker counseling and diagnostic disclosure
Study NCT06017830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical treatment agents
Description: Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
Study NCT04871035 — intervention group
Intervention type: DEVICE
Intervention: Immunoadsorption
Description: 1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.
Study NCT04871035 — intervention group
Intervention type: DEVICE
Intervention: Plasma Exchange
Description: 1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.
Study NCT05720234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.
Study NCT05348967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TECADRIOL
Description: Food supplement with D-chiro-inositol and alpha-lactalbumin
Study NCT05556317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistive exercise
Description: advices and resistive exercise
Study NCT05556317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistive exercise
Description: advices and resistive exercise
Study NCT04667013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine nitrone (TBN) tablet / Placebo
Description: Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
Study NCT06053554 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phakoemulsification
Description: Femtolaser is used to perform a standard 5.0mm CCC centred on the pupil or limbus and to fragment the lens nucleus toguarantee reproducible results in every eye.After the CCC and nucleus fragmentation the anterior segment is filled with viscoelastics, the rhexis lenticule is removed and hydrodisection of the nucleus is performed. Subsequently phacoemulsification for nucleus and irrigation/aspiration of the lens cortex is performed. The capsular bag and AC is then filled with a cohesive viscoelastic and the IOL is implanted with the haptics in the back or with the haptics in the sulcus. At the end of surgery, the viscoelastic is removed using the irrigation aspiration probe, intracameral antibiotic is instilled, the CCI and paracenteses are hydrated and sealed.
Study NCT06053554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ziemer Z8 Femtolaser
Description: The femto second laser used for certain steps (capsulorhexis, nucleus fragmentation) of the cataract surgery.
Study NCT06053554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Kowa Avansee Preset
Description: The used 3 piece intra ocular lens
Study NCT06623123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oto Smartphone Application (Oto Health Ltd)
Description: The smartphone application delivers personalized tinnitus therapy combining evidence-based CBT with mindfulness, patient education as well as physical therapy such as stretches and exercises. There are additional sounds available to listen to from the sound library. There will be a structured programme that the participants can work through however they are encouraged to personalise their own therapy.
Study NCT05996952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.
Study NCT05835297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise interventions
Description: Participants will undergo a 12-week multicomponent exercise regimen, twice per week on non-consecutive days for 45-60 min each. The session will be divided into 4 min of warm-up; range of motion exercises of upper and lower extremities, followed by light walking, then 8 min balance exercises, followed by 15 min strength exercises; two sets of 13-15 repetitions maximum of chair rises with progression, two sets of 13-15 repetitions of modified squats (holding a chair backrest if needed) with progression, 2 sets of 20-30 repetitions of seated or 2 sets of 13-15 repetitions of standing calf raises, then 15 min aerobic exercises; five 3-min bouts of walking between two strengthening exercises and/or 2 balance exercises, finally 3 min cool down exercises of light walking and stretching exercises.
Study NCT06623123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tinnitus Retraining Therapy (TRT)
Description: Tinnitus-retraining therapy will be offered in the control arm which represents the standard evidence-based intervention on the NHS. (2) Participants enrolled to this arm will undertake tinnitus retraining therapy with a trained audiologist. The sessions will last 30 minutes with the option for further sessions should the patient which to have more support with their tinnitus to mimic the NHS programme as much as possible. These sessions will encompass a brief audiological history followed by therapy tailored to the patient's needs allowing for patient-centred optimisation of tinnitus burden and secondary comorbidities. This may include relaxation, CBT and advice surrounding sound as well as white noise masking therapy.
Study NCT06667934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
Description: Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
Study NCT06667934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methalazine suppository was given rectally once a day
Description: Methalazine suppository was given rectally once a day
Study NCT06598462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solrikitug Low Dose
Description: Solrikitug low dose subcutaneous injection
Study NCT06598462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solrikitug Mid Dose
Description: Solrikitug mid dose subcutaneous injection
Study NCT06598462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solrikitug High Dose
Description: Solrikitug high dose subcutaneous injection
Study NCT06598462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT06675435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Description: 20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
Study NCT06683105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyIBDDiet app
Description: Participants in the Standard of Care arm will be administered the intervention (using the app) for 30 days, and participants in the MYIBDDiet arm will use the app for 60 days.